{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:21:12Z","timestamp":1787667672467,"version":"build-2736575974"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T00:00:00Z","timestamp":1680134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The efficacy of dupilumab as biological treatment of severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) depends on its ability to inhibit the pathophysiologic mechanisms involved in type 2 inflammation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To assess in a large sample of subjects with severe asthma, the therapeutic impact of dupilumab in real-life, with regard to positive or negative skin prick test (SPT) and CRSwNP presence or absence.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Clinical, functional, and laboratory parameters were measured at baseline and 24 weeks after the first dupilumab administration. Moreover, a comparative evaluation was carried out in relation to the presence or absence of SPT positivity and CRSwNP.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among the 127 recruited patients with severe asthma, 90 had positive SPT, while 78 reported CRSwNP. Compared with the 6 months preceding the first dupilumab injection, asthma exacerbations decreased from 4.0 (2.0-5.0) to 0.0 (0.0-0.0) (p &amp;lt; 0.0001), as well as the daily prednisone intake fell from 12.50 mg (0.00-25.00) to 0.00 mg (0.00-0.00) (p &amp;lt; 0.0001). In the same period, asthma control test (ACT) score increased from 14 (10-18) to 22 (20-24) (p &amp;lt; 0.0001), and sino-nasal outcome test (SNOT-22) score dropped from 55.84 \u00b1 20.32 to 19.76 \u00b1 12.76 (p &amp;lt; 0.0001). Moreover, we observed relevant increases in forced expiratory volume in one second (FEV1) from the baseline value of 2.13 L (1.62-2.81) to 2.39 L (1.89-3.06) (p &amp;lt; 0.0001). Fractional exhaled nitric oxide (FeNO) values decreased from 27.0 ppb (18.0-37.5) to 13.0 ppb (5.0-20.0) (p &amp;lt; 0.0001). These improvements were quite similar in subgroups of patients characterized by SPT negativity or positivity, and CRSwNP absence or presence. No statistically significant correlations were detected between serum IgE levels, baseline blood eosinophils or FeNO levels and dupilumab-induced changes, with the exception of FEV1 increase, which was shown to be positively correlated with FeNO values (r = 0.3147; p &amp;lt; 0.01).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our results consolidate the strategic position of dupilumab in its role as an excellent therapeutic option currently available within the context of modern biological treatments of severe asthma and CRSwNP, frequently driven by type 2 airway inflammation.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1121237","type":"journal-article","created":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T11:59:28Z","timestamp":1680177568000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":42,"title":["Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps"],"prefix":"10.3389","volume":"14","author":[{"given":"Corrado","family":"Pelaia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alida","family":"Benfante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Busceti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Filomena","family":"Caiaffa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Campisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna Elisiana","family":"Carpagnano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nunzio","family":"Crimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"D\u2019Amato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Pia","family":"Foschino Barbaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelantonio","family":"Maglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Minenna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santi","family":"Nolasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Paglino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Papia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girolamo","family":"Pelaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Portacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Ricciardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Scichilone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Scioscia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Triggiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Valenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Vatrella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Crimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10051064","article-title":"Novel biological therapies for severe asthma endotypes","volume":"10","author":"Pelaia","year":"2022","journal-title":"Biomedicines"},{"key":"B2","unstructured":"GINA report: Global strategy for asthma management and prevention2022"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2017.1387245","article-title":"Dupilumab for the treatment of asthma","volume":"17","author":"Pelaia","year":"2017","journal-title":"Expert Opin Biol Ther"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9091096","article-title":"The role of dupilumab in severe asthma","volume":"9","author":"Ricciardolo","year":"2021","journal-title":"Biomedicines"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-013-0373-9","article-title":"Role of interleukin-13 in asthma","volume":"13","author":"Corren","year":"2013","journal-title":"Curr Allergy Asthma Rep"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00068712","article-title":"Interleukin-13 induces collagen type-1 expression through matrix metalloproteinase-2 and transforming growth factor-\u03b21 in airway fibroblasts in asthma","volume":"43","author":"Firszt","year":"2014","journal-title":"Eur Respir J"},{"key":"B7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrd4624","article-title":"Targeting key proximal drivers of type 2 inflammation in disease","volume":"15","author":"Gandhi","year":"2016","journal-title":"Nat Rev Drug Discovery"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.1.51.pe55","article-title":"Untangling the complex web of IL-4- and IL-13-mediated signaling pathways","volume":"1","author":"Wills-Karp","year":"2008","journal-title":"Sci Signal"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1126\/science.1085458","article-title":"Interleukin-4 and interleukin-13 signaling connections maps","volume":"300","author":"Kelly-Welch","year":"2003","journal-title":"Science"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.851940","article-title":"Interleukins 4 and 13 in asthma: Key pathophysiologic cytokines and druggable molecular targets","volume":"13","author":"Pelaia","year":"2022","journal-title":"Front Pharmacol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/S2213-2600(21)00322-2","article-title":"Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study","volume":"10","author":"Wechsler","year":"2022","journal-title":"Lancet Respir Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): Results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/cea.13614","article-title":"Effectiveness and safety of dupilumab for the treatment of severe asthma in a real-life French multi-centre adult cohort","volume":"50","author":"Dupin","year":"2020","journal-title":"Clin Exp Allergy"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/all.14338","article-title":"Efficacy of dupilumab in atopic comorbidities associated with moderate-to-severe adult atopic dermatitis","volume":"10","author":"Nettis","year":"2020","journal-title":"Allergy"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2147\/JAA.S312123","article-title":"Real-world experience with dupilumab in severe asthma: one-year data from an Italian named patient program","volume":"14","author":"Campisi","year":"2021","journal-title":"J Asthma Allergy"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2147\/JAA.S328988","article-title":"Short-term evaluation of dupilumab effects in patients with severe asthma and nasal polyposis","volume":"14","author":"Pelaia","year":"2021","journal-title":"J Asthma Allergy"},{"key":"B19","doi-asserted-by":"publisher","first-page":"395","DOI":"10.2147\/JAA.S357548","article-title":"Real-world effectiveness of dupilumab for patients with severe asthma: A retrospective study","volume":"15","author":"Numata","year":"2022","journal-title":"J Asthma Allergy"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur Respir J"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(87)90360-5","article-title":"The determination of the eosinophil count: comparison of two techniques","volume":"79","author":"Laufer","year":"1987","journal-title":"J Allergy Clin Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/978-1-4939-1173-8_7","article-title":"The absolute basophil count","volume":"1192","author":"Borzova","year":"2014","journal-title":"Methods Mol Biol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jaci.2003.09.008","article-title":"Development of the asthma control test: A survey for assessing asthma control","volume":"113","author":"Nathan","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201908-1590ST","article-title":"Standardization of spirometry 2019 update. an official American thoracic society and European respiratory society technical statement","volume":"200","author":"Graham","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200406-710ST","article-title":"ATS\/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005","volume":"171","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1600965","DOI":"10.1183\/13993003.00965-2016","article-title":"A European respiratory society technical standard: Exhaled biomarkers in lung disease","volume":"49","author":"Horv\u00e1th","year":"2017","journal-title":"Eur Respir J"},{"key":"B27","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","article-title":"Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting \u03b22 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial","volume":"388","author":"Wenzel","year":"2016","journal-title":"Lancet"},{"key":"B28","doi-asserted-by":"publisher","first-page":"97","DOI":"10.18176\/jiaci.0682","article-title":"Dupilumab: A review of present indications and off-label uses","volume":"32","author":"Mu\u00f1oz-Bellido","year":"2022","journal-title":"J Investig Allergol Clin Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4193\/Rhino12.000","article-title":"EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists","volume":"50","author":"Fokkens","year":"2012","journal-title":"Rhinology"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1177\/2058738420950851","article-title":"Real-life of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma","volume":"34","author":"Lombardo","year":"2020","journal-title":"Int J Immunopathol Pharmacol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1111\/j.1398-9995.1984.tb01979.x","article-title":"Skin prick testing and the use of histamine references","volume":"39","author":"Malling","year":"1984","journal-title":"Allergy"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.12.006","article-title":"An expert consensus framework for asthma remission as a treatment goal","volume":"145","author":"Menzies-Gow","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2102583","DOI":"10.1183\/13993003.02583-2021","article-title":"Asthma remission: what is it and how can it be achieved","volume":"60","author":"Thomas","year":"2022","journal-title":"Eur Respir J"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2018.10.016","article-title":"The severe asthma network in Italy: findings and perspectives","volume":"7","author":"Heffler","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B35","doi-asserted-by":"publisher","first-page":"100007","DOI":"10.1016\/j.waojou.2018.12.001","article-title":"Shadow cost of oral corticosteroids-related adverse events: A pharmacoeconomic evaluation applied to real-life data from the severe asthma network in Italy (SANI) registry","volume":"12","author":"Canonica","year":"2019","journal-title":"World Allergy Organ J"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2022.02.026","article-title":"Dupilumab demonstrates rapid onset of response across three type 2 inflammatory diseases","volume":"10","author":"Canonica","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2003393","DOI":"10.1183\/13993003.03393-2020","article-title":"Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation","volume":"58","author":"Busse","year":"2021","journal-title":"Eur Respir J"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2018.07.029","article-title":"Use of biomarkers to identify phenotypes and endotypes of severe asthma","volume":"121","author":"Carr","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1080\/20018525.2021.1891725","article-title":"Fractional exhaled nitric oxide as a determinant for the clinical course of asthma: A systematic review","volume":"8","author":"Ulrik","year":"2021","journal-title":"Eur Clin Respir J"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.2174\/0929867327666200713184659","article-title":"An emerging role for exhaled nitric oxide in guiding biological treatment in severe asthma","volume":"27","author":"Rolla","year":"2020","journal-title":"Curr Med Chem"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2021.02.013","article-title":"Innate and adaptive immunity: ILC2 and Th2 cells in upper and lower airway allergic diseases","volume":"9","author":"Scadding","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.02.016","article-title":"The basic immunology of asthma","volume":"184","author":"Hammad","year":"2021","journal-title":"Cell"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-110119-091711","article-title":"Group 2 innate lymphoid cells: team players in regulating asthma","volume":"39","author":"Rodriguez-Rodriguez","year":"2021","journal-title":"Annu Rev Immunol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1080\/1744666X.2020.1860755","article-title":"The emerging role of type 2 inflammation in asthma","volume":"17","author":"Matucci","year":"2021","journal-title":"Expert Rev Clin Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2019.01514","article-title":"Interleukin-5 in the pathophysiology of severe asthma","volume":"10","author":"Pelaia","year":"2019","journal-title":"Front Physiol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2022.107058","article-title":"Efficacy and safety of dupilumab as add-on therapy for patients with severe asthma: A real-world Dutch cohort study","volume":"206","author":"Thelen","year":"2023","journal-title":"Respir Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12091526","article-title":"Effectiveness of dupilumab in the treatment of patients with uncontrolled severe CRSwNP: A \u201cReal-life\u201d observational study in na\u00efve and post-surgical patients","volume":"12","author":"Ottaviano","year":"2022","journal-title":"J Pers Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11102684","article-title":"Effectiveness of dupilumab in the treatment of patients with severe uncontrolled CRSwNP: A \u201cReal-life\u201d observational study in the first year of treatment","volume":"11","author":"De Corso","year":"2022","journal-title":"J Clin Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1121237\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T11:59:31Z","timestamp":1680177571000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1121237\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,30]]},"references-count":48,"alternative-id":["10.3389\/fimmu.2023.1121237"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1121237","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,30]]},"article-number":"1121237"}}